Watch for the initiation of the Phase 1/2 trial and any early safety/efficacy data readouts in 2027. The stock may react to enrollment updates or competitive developments in AATD gene editing space.
Price Chart
Executive Summary
Prime Medicine announced FDA clearance of its IND application for PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). This is a key pipeline milestone that enables the company to initiate a Phase 1/2 clinical trial in 2027, targeting the ~100,000 US patients with the PiZZ genotype. The clearance builds on recent regulatory progress for PM577a (Wilson disease) and demonstrates platform modularity, but the stock has historically been volatile around such events.
Key Facts
- FDA cleared IND for PM647, an in vivo Prime Editor for AATD targeting the E342K (Pi*Z) mutation in SERPINA1.
- Phase 1/2 trial is global, single-arm, open-label, first-in-human; initial clinical data expected in 2027.
- Approximately 100,000 people in the US carry the PiZZ genotype; ~200,000 across US and Europe.
- PM647 uses the same liver-directed LNP as PM577a (Wilson disease), highlighting platform modularity.
- In humanized mouse models, PM647 achieved high editing efficiency and restored M-AAT protein into the healthy human range at clinically relevant doses.
Financial Impact
No financial terms disclosed; IND clearance is a non-financial regulatory milestone. The company is pre-revenue with no approved products.
Risk Factors
- Clinical trial failure or safety concerns could halt development.
- Competing therapies (e.g., Vertex/CRISPR, Beam) may reach market first.
- No revenue or near-term commercial path; cash burn and dilution risk remain.
- Historical stock volatility around pipeline events (prior IND clearances saw large swings).
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | Press Release | $2.90 | awaiting T+60 | — | $3.61 (+24.48%) |
Aug 6, 2026 11w ago | 8-K | $2.95 | awaiting T+60 | — | $3.61 (+22.37%) |
Jul 8, 2026 15w ago | 8-K | $4.62 $3.06 | ▼ −33.87% | ▼ −36.19% | $3.61 (−21.86%) |
Jun 18, 2026 18w ago | Press Release | $3.23 $3.18 | ▼ −1.55% | ▼ −3.44% | $3.61 (+11.76%) |
May 7, 2026 24w ago | 8-K | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.61 (−15.89%) |
May 7, 2026 24w ago | Press Release | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.61 (−15.89%) |
Apr 16, 2026 27w ago | 8-K | $3.67 $3.52 | ▼ −4.22% | ▼ −11.27% | $3.61 (−1.63%) |
Mar 3, 2026 33w ago | Press Release | $4.23 $3.30 | ▼ −21.99% | ▼ −32.30% | $3.61 (−14.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers